Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 23
20
Diseases
83
Unique genes
0.193
Avg. similarity score
Bilateral multicystic dysplastic kidney
Most-connected disease (10 links)
Disease
Searched: polycystic liver disease 2
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
polycystic liver disease 2
Bilateral multicystic dysplastic kidney
Giant cell tumor of tendon sheath
Polycystic liver disease
Renal dysplasia
17q12 microdeletion syndrome
Multicystic dysplastic kidney
Hyperuricemic nephropathy
Tubulointerstitial kidney disease
Mayer-rokitansky-kuster-hauser syndrome
Ovarian mucinous adenocarcinoma
Polycystic kidney disease
Renal cysts and diabetes syndrome
Uterine cancer
SEC61A1 deficiency
ALG9-associated autosomal dominant polycystic kidney disease
autosomal dominant medullary cystic kidney disease with or without hyperuricemia
polycystic kidney disease 3 with or without polycystic liver disease
polycystic liver disease 1
SEC61B-related polycystic liver disease
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Bilateral multicystic dysplastic kidney | 10 | 10 | 1 |
| Giant cell tumor of tendon sheath | 9 | 9 | 1 |
| Polycystic liver disease | 9 | 9 | 23 |
| Renal dysplasia | 9 | 9 | 1 |
| 17q12 microdeletion syndrome | 8 | 8 | 2 |
| Multicystic dysplastic kidney | 8 | 8 | 1 |
| Hyperuricemic nephropathy | 7 | 7 | 5 |
| Tubulointerstitial kidney disease | 6 | 6 | 9 |
| Mayer-rokitansky-kuster-hauser syndrome | 5 | 5 | 7 |
| Ovarian mucinous adenocarcinoma | 5 | 5 | 6 |
| Polycystic kidney disease | 5 | 5 | 48 |
| Renal cysts and diabetes syndrome | 5 | 5 | 3 |
| Uterine cancer | 5 | 5 | 4 |
| SEC61A1 deficiency | 3 | 3 | 1 |
| polycystic liver disease 2 | 3 | 3 | 1 |
| ALG9-associated autosomal dominant polycystic kidney disease | 2 | 2 | 1 |
| autosomal dominant medullary cystic kidney disease with or without hyperuricemia | 2 | 2 | 2 |
| polycystic kidney disease 3 with or without polycystic liver disease | 2 | 2 | 1 |
| polycystic liver disease 1 | 2 | 2 | 1 |
| SEC61B-related polycystic liver disease | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| HNF1B | 12 / 20 | 17q12 microdeletion syndrome, Bilateral multicystic dysplastic kidney, Giant cell tumor of tendon sheath, Hyperuricemic nephropathy and 8 more |
| SEC61A1 | 4 / 20 | Hyperuricemic nephropathy, Polycystic liver disease, SEC61A1 deficiency, Tubulointerstitial kidney disease |
| SEC63 | 4 / 20 | Polycystic kidney disease, Polycystic liver disease, polycystic liver disease 2, Tubulointerstitial kidney disease |
| ALG9 | 3 / 20 | ALG9-associated autosomal dominant polycystic kidney disease, Polycystic kidney disease, Polycystic liver disease |
| GANAB | 3 / 20 | Polycystic kidney disease, polycystic kidney disease 3 with or without polycystic liver disease, Polycystic liver disease |
| PRKCSH | 3 / 20 | Polycystic kidney disease, Polycystic liver disease, polycystic liver disease 1 |
| UMOD | 3 / 20 | autosomal dominant medullary cystic kidney disease with or without hyperuricemia, Hyperuricemic nephropathy, Tubulointerstitial kidney disease |
| ALG8 | 2 / 20 | Polycystic kidney disease, Polycystic liver disease |
| APOA4 | 2 / 20 | autosomal dominant medullary cystic kidney disease with or without hyperuricemia, Tubulointerstitial kidney disease |
| DKK3 | 2 / 20 | Polycystic kidney disease, Polycystic liver disease |
| LRP5 | 2 / 20 | Polycystic kidney disease, Polycystic liver disease |
| LRP6 | 2 / 20 | Polycystic kidney disease, Polycystic liver disease |
| ONECUT2 | 2 / 20 | Polycystic kidney disease, Polycystic liver disease |
| PKD2 | 2 / 20 | Polycystic kidney disease, Polycystic liver disease |
| PKHD1 | 2 / 20 | Polycystic kidney disease, Polycystic liver disease |
| REN | 2 / 20 | Hyperuricemic nephropathy, Tubulointerstitial kidney disease |
| RUVBL1 | 2 / 20 | Polycystic liver disease, Tubulointerstitial kidney disease |
| SEC61B | 2 / 20 | Polycystic liver disease, SEC61B-related polycystic liver disease |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Thyroid hormone signaling pathway | KEGG | 9 / 122 | 10.7× | 1.50e-7 | 9.99e-6 ✓ sig. |
| Breast cancer | KEGG | 8 / 148 | 7.8× | 7.95e-6 | 2.96e-4 ✓ sig. |
| Gastric cancer | KEGG | 8 / 150 | 7.7× | 8.78e-6 | 3.20e-4 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 8 / 170 | 6.8× | 2.19e-5 | 6.79e-4 ✓ sig. |
| Maturity onset diabetes of the young | KEGG | 4 / 26 | 22.3× | 2.82e-5 | 8.38e-4 ✓ sig. |
| Proteoglycans in cancer | KEGG | 8 / 204 | 5.7× | 8.00e-5 | 1.95e-3 ✓ sig. |
| Thyroid cancer | KEGG | 4 / 37 | 15.6× | 1.18e-4 | 2.64e-3 ✓ sig. |
| AMPK signaling pathway | KEGG | 6 / 122 | 7.1× | 1.94e-4 | 3.92e-3 ✓ sig. |
| GAB1 signalosome | Reactome | 3 / 17 | 25.5× | 2.02e-4 | 4.05e-3 ✓ sig. |
| ErbB signaling pathway | KEGG | 5 / 86 | 8.4× | 3.14e-4 | 5.72e-3 ✓ sig. |
| Colorectal cancer | KEGG | 5 / 87 | 8.3× | 3.31e-4 | 5.99e-3 ✓ sig. |
| Trafficking of myristoylated proteins to the cilium | Reactome | 2 / 5 | 57.9× | 4.66e-4 | 7.84e-3 ✓ sig. |
| Calnexin/calreticulin cycle | Reactome | 2 / 5 | 57.9× | 4.66e-4 | 7.84e-3 ✓ sig. |
| Signaling pathways regulating pluripotency of stem cells | KEGG | 6 / 144 | 6.0× | 4.73e-4 | 7.95e-3 ✓ sig. |
| N-Glycan biosynthesis | KEGG | 4 / 55 | 10.5× | 5.53e-4 | 8.94e-3 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| kidney development | GO:0001822 | 19 / 146 | 29.3× | 4.60e-23 | 1.15e-19 ✓ sig. |
| mesonephric tubule development | GO:0072164 | 6 / 7 | 193× | 4.46e-14 | 2.63e-11 ✓ sig. |
| determination of left/right symmetry | GO:0007368 | 11 / 83 | 29.8× | 8.33e-14 | 4.63e-11 ✓ sig. |
| mesonephric duct development | GO:0072177 | 5 / 6 | 188× | 9.15e-12 | 3.38e-9 ✓ sig. |
| branching involved in ureteric bud morphogenesis | GO:0001658 | 8 / 45 | 40.0× | 2.02e-11 | 6.98e-9 ✓ sig. |
| pronephros development | GO:0048793 | 5 / 7 | 161× | 3.19e-11 | 1.05e-8 ✓ sig. |
| non-motile cilium assembly | GO:1905515 | 8 / 57 | 31.6× | 1.49e-10 | 4.15e-8 ✓ sig. |
| liver development | GO:0001889 | 9 / 87 | 23.3× | 1.67e-10 | 4.62e-8 ✓ sig. |
| cilium assembly | GO:0060271 | 12 / 237 | 11.4× | 5.74e-10 | 1.38e-7 ✓ sig. |
| mesonephros development | GO:0001823 | 5 / 13 | 86.6× | 1.91e-9 | 4.01e-7 ✓ sig. |
| heart development | GO:0007507 | 12 / 273 | 9.9× | 2.86e-9 | 5.68e-7 ✓ sig. |
| anatomical structure morphogenesis | GO:0009653 | 9 / 160 | 12.7× | 3.77e-8 | 5.36e-6 ✓ sig. |
| positive regulation of DNA-templated transcription | GO:0045893 | 17 / 778 | 4.9× | 4.41e-8 | 6.13e-6 ✓ sig. |
| Wnt signaling pathway | GO:0016055 | 10 / 232 | 9.7× | 7.89e-8 | 1.01e-5 ✓ sig. |
| negative regulation of mesenchymal cell apoptotic process involved in metanephros development | GO:1900212 | 3 / 3 | 225× | 8.45e-8 | 1.06e-5 ✓ sig. |